Enzychem Lifesciences's investigational new drug application (IND) for chemoradiation induced oral mucositis had ... - Markets Insider

Enzychem Lifesciences's investigational new drug application (IND) for chemoradiation induced oral mucositis had ... Markets Insider Probably 60 to 70 percent of patients with cancers of the oral cavity, oral pharynx, hypopharynx, and nasopharynx, develop severe mucositis of such severity as to require increased hospitalization, emergency room visits, or breaks in treatment ...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uZ15yX
via IFTTT